JP2012504560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504560A5 JP2012504560A5 JP2011529448A JP2011529448A JP2012504560A5 JP 2012504560 A5 JP2012504560 A5 JP 2012504560A5 JP 2011529448 A JP2011529448 A JP 2011529448A JP 2011529448 A JP2011529448 A JP 2011529448A JP 2012504560 A5 JP2012504560 A5 JP 2012504560A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- formula
- abuse
- schizophrenia
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 5
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 2
- 208000028810 Shared psychotic disease Diseases 0.000 claims 2
- 206010043903 Tobacco abuse Diseases 0.000 claims 2
- 206010001584 alcohol abuse Diseases 0.000 claims 2
- 208000025746 alcohol use disease Diseases 0.000 claims 2
- 201000001272 cocaine abuse Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000003176 neuroleptic agent Substances 0.000 claims 2
- 230000000701 neuroleptic effect Effects 0.000 claims 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10237708P | 2008-10-03 | 2008-10-03 | |
| DKPA200801392 | 2008-10-03 | ||
| US61/102,377 | 2008-10-03 | ||
| DKPA200801392 | 2008-10-03 | ||
| US17639209P | 2009-05-07 | 2009-05-07 | |
| US61/176,392 | 2009-05-07 | ||
| DKPA200900591 | 2009-05-07 | ||
| DKPA200900591 | 2009-05-07 | ||
| PCT/DK2009/050258 WO2010037398A1 (en) | 2008-10-03 | 2009-10-01 | Oral formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012504560A JP2012504560A (ja) | 2012-02-23 |
| JP2012504560A5 true JP2012504560A5 (enExample) | 2012-11-15 |
Family
ID=41217546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529448A Pending JP2012504560A (ja) | 2008-10-03 | 2009-10-01 | 経口製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110178094A1 (enExample) |
| EP (1) | EP2344163A1 (enExample) |
| JP (1) | JP2012504560A (enExample) |
| KR (1) | KR20110081176A (enExample) |
| CN (1) | CN102170884A (enExample) |
| AR (1) | AR073755A1 (enExample) |
| AU (1) | AU2009298264A1 (enExample) |
| BR (1) | BRPI0919165A2 (enExample) |
| CA (1) | CA2732613A1 (enExample) |
| CO (1) | CO6321158A2 (enExample) |
| EA (1) | EA201170512A1 (enExample) |
| IL (1) | IL210235A0 (enExample) |
| MX (1) | MX2011001044A (enExample) |
| NZ (1) | NZ590897A (enExample) |
| WO (1) | WO2010037398A1 (enExample) |
| ZA (1) | ZA201102446B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101157272B1 (ko) | 2003-07-22 | 2012-06-15 | 아레나 파마슈티칼스, 인크. | 5?ｈｔ2ａ 세로토닌 수용체의 조절자로서 이와 관련된질환의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴우레아 유도체 |
| WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| CA2722374A1 (en) * | 2008-05-07 | 2009-11-12 | H. Lundbeck A/S | Method for treating cognitive deficits |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| RS58546B1 (sr) | 2011-06-20 | 2019-05-31 | H Lundbeck As | Deuterizovani 1-piperazino-3-fenil indani za tretiranje šizofrenije |
| JO3421B1 (ar) * | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| AU2016291673A1 (en) | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
| CN112930341A (zh) | 2018-10-29 | 2021-06-08 | H.隆德贝克有限公司 | 无定形的具有式(i)的化合物和无定形的具有式(i)的化合物的盐 |
| JP7583719B2 (ja) | 2018-12-03 | 2024-11-14 | ハー・ルンドベック・アクチエゼルスカベット | ４－（（１Ｒ，３Ｓ）－６－クロロ－３－フェニル－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－１，２，２－トリメチルピペラジン及び４－（（１Ｒ，３Ｓ）－６－クロロ－３－（フェニル－ｄ５）－２，３－ジヒドロ－１Ｈ－インデン－１－イル）－２，２－ジメチル－１－（メチル－ｄ３）ピペラジンのプロドラッグ |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4031216A (en) * | 1974-08-12 | 1977-06-21 | Knoll A.G. Chemische Fabriken | 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines |
| IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
| DE3139970A1 (de) * | 1981-10-08 | 1983-04-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5026853A (en) * | 1987-04-01 | 1991-06-25 | Janssen Pharmaceutica N.V. | 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| CA2091204C (en) * | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| DK55192D0 (da) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| CA2132411A1 (en) * | 1994-09-19 | 1996-03-20 | Michael Trani | Enzymatic esterification of long-chain racemic acids and alcohols |
| US6410794B1 (en) * | 1994-12-16 | 2002-06-25 | Uop Llc | Process for preparation of pharmaceutically desired chiral tetralone from tetralones |
| US6455736B1 (en) * | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| US5807897A (en) * | 1996-03-01 | 1998-09-15 | Zeneca Limited | Aminotetralin derivative and compositions and method of use thereof |
| DK1073618T3 (da) * | 1998-05-01 | 2004-03-15 | Pfizer Prod Inc | Fremgangsmåde til fremstilling af enantiomerisk ren eller optisk beriget sertralin-tetralon under anvendelse af kontinuerlig kromatografi |
| IN187170B (enExample) * | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
| EP1465601A4 (en) * | 2001-12-28 | 2006-02-15 | Teva Pharma | STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD |
| US7772240B2 (en) * | 2003-08-18 | 2010-08-10 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| EP1853575A1 (en) * | 2005-02-16 | 2007-11-14 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| TWI376373B (en) * | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
| AU2007283196A1 (en) * | 2006-08-10 | 2008-02-14 | Cipla Limited | Antiretroviral solid oral composition |
| CA2722374A1 (en) * | 2008-05-07 | 2009-11-12 | H. Lundbeck A/S | Method for treating cognitive deficits |
-
2009
- 2009-10-01 NZ NZ590897A patent/NZ590897A/en not_active IP Right Cessation
- 2009-10-01 EA EA201170512A patent/EA201170512A1/ru unknown
- 2009-10-01 BR BRPI0919165A patent/BRPI0919165A2/pt not_active Application Discontinuation
- 2009-10-01 CN CN200980139559XA patent/CN102170884A/zh active Pending
- 2009-10-01 AU AU2009298264A patent/AU2009298264A1/en not_active Abandoned
- 2009-10-01 KR KR1020117007586A patent/KR20110081176A/ko not_active Withdrawn
- 2009-10-01 MX MX2011001044A patent/MX2011001044A/es active IP Right Grant
- 2009-10-01 CA CA2732613A patent/CA2732613A1/en not_active Abandoned
- 2009-10-01 US US13/119,846 patent/US20110178094A1/en not_active Abandoned
- 2009-10-01 WO PCT/DK2009/050258 patent/WO2010037398A1/en not_active Ceased
- 2009-10-01 EP EP09776299A patent/EP2344163A1/en not_active Withdrawn
- 2009-10-01 JP JP2011529448A patent/JP2012504560A/ja active Pending
- 2009-10-02 AR ARP090103813A patent/AR073755A1/es unknown
-
2010
- 2010-12-23 IL IL210235A patent/IL210235A0/en unknown
-
2011
- 2011-03-29 CO CO11037985A patent/CO6321158A2/es not_active Application Discontinuation
- 2011-04-01 ZA ZA2011/02446A patent/ZA201102446B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012504560A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| JP2011519846A5 (enExample) | ||
| JP2010529118A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2009242409A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2013509429A5 (enExample) | ||
| NZ599770A (en) | New ccr2 receptor antagonists and uses thereof | |
| JP2017528503A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| EP2011487A3 (en) | Pharmaceutical compositions for gastroinetestinal drug delivery | |
| JP2013014622A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2015505296A5 (enExample) | ||
| JP2010519260A5 (enExample) | ||
| PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
| JP2015529234A5 (enExample) | ||
| CA2682494A1 (en) | Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2020005735A (es) | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. | |
| JP2010521516A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| ATE479433T1 (de) | Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel |